SUMMARY The topical effect of methotrexate (MTX) on small intestinal hexose and ion transport has been studied using an in vivo steady state jejunal perfusion technique in the rat, and short circuited rabbit terminal ileum in Ussing chambers in vitro. In rat jejunum, perfusion with MTX (1 umol/l) caused significant reductions in water, sodium, and glucose absorption within 110 minutes of exposure. Fructose absorption was, however, unimpaired. The same concentration of MTX, when added to the mucosal side of distal rabbit ileum caused significant increases in transmucosal potential difference, short circuit current and the unidirectional flux of chloride from serosa to mucosa. In the presence of a subphysiological magnesium concentration (0.3 mmol/l), MTX resulted in the abolition of net sodium absorption and the conversion of net chloride absorption to secretion. We conclude that MTX has a topical effect on small intestinal transport which is independent of its effect on crypt cell kinetics. The present study was undertaken to determine whether enteral methotrexate in low doses, unlikely to cause changes in villous architecture, is associated
The early use of folic acid antagonists in cancer chemotherapy was associated with severe intestinal toxicity and extensive ulceration of small and large intestine occurred as a result of depressed crypt cell regeneration.' In experimental animal, high dose or prolonged continuous methotrexate almost invariably results in hypoplastic villous atrophy, which causes malabsorption of a wide range of nutrients and drugs.2 In clinical practice, low dose methotrexate may also be associated with enterotoxicity and children with acute leukaemia receiving maintenance low dose. MTX have impaired d-xylose absorption.3 4 Similar observations have been made in the rat where an eight day course of low dose aminopterin (a close analogue of methotrexate) resulted in hexose malabsorption but no morphological change.5 Although severe enterotoxicity on low dose methotrexate is unusual, protracted diarrhoea has been reported6 and it has been postulated that the drug may be responsible for poor weight gain in some patients7 and possibly the malabsorption of other drugs.8
The present study was undertaken to determine whether enteral methotrexate in low doses, unlikely to cause changes in villous architecture, is associated with disturbances in intestinal transport which might contribute to diarrhoea. Effects on water and hexose transport were investigated using a steadystate perfusion technique in rat jejunum in vivo and effects on ion transport studied using short circuited rabbit distal ileum in vitro. There is good evidence that hypomagnesaemia is a complication of diarrhoeal disorders, particularly those associated with an impaired intake of oral fluids and nutrients. The changes in intestinal transport associated with local MTX cannot be explained on the basis of such effects on intestinal epithelial cell turnover and appear to result as a direct effect on the enterocyte. Dihydrofolate reductase is also an important coenzyme in a number of other one carbon transfer reactions and consequently the synthesis of RNA and protein in mature cells may also be influenced by MTX.19 Previous studies have suggested that the mature villous enterocyte is affected by this non-S phase action. Within four hours of a single high dose of aminopterin, given systemically, there was a marked reduction in mucosal oxygen consumption and glycolysis20 and patchy cytoplasmic vacuolation is seen in villous enterocytes within three hours of low dose MTX administration in both children with leukaemia and adults with psoriasis. 17 27 The precise mechanism of this early systemic effect is unclear, but may be due to disruption of cellular enzyme systems as a result of the inhibition of protein synthesis.
In the rat jejunum in vivo, the progressive decreases in net sodium, water and glucose absorption associated with local exposure to MTX could not be reproduced by folic acid, a close structural analogue of MTX, suggesting that impaired absorption is not simply because of competition by MTX for glucose binding sites. Fructose was normally absorbed in the presence of MTX. This preservation of fructose absorption, which occurs passively by a carrier mediated process, but inhibition of active glucose absorption supports the notion that MTX does not act directly on brush border membrane transport. It seems more likely that it inhibits one or more of those intracellular events which follow and are necessary for continuing glucose absorption.22 Studies by Kaminskas 3 support this hypothesis. In an Erlich ascites tumour cell preparation it was shown that MTX rapidly inhibited glycolysis, depressed cellular ATP and impaired glucose uptake. The latter was restored by correction of ATP depletion. There was no evidence that MTX affected the saturation characteristics of glucose transport and the changes in uptake were observed before suppression of protein synthesis by MTX became apparent.
Although high dose systemic MTX leads to reduced activity of Na+K+ ATPase in rat jejunal enterocytes within 48 hours24 the role of this enzyme in the mediation of the currently reported changes is unknown.
In addition to effects on jejunal hexose transport topical MTX also induces early and marked changes in rabbit ileal electrolyte transport in vitro. These changes are exaggerated, both quantitatively and qualitatively, in the presence of sub-physiological concentrations of Mg. A similar enhancement has been observed in the secretory response of ileum to high Mg concentrations in vitro. 13 Although intestinal secretion has been previously described in association with radiation enteropathy,25 the changes in transport currently described occur in the absence of gross mucosal morphological changes. Taminiau et a124 have reported reduction in net sodium fluxes, in response to glucose, after systemic MTX, but did not examine the effects on chloride transport in their experiments. An early effect upon intracellular glycolysis has previously been reported23 but the relevance of this to our findings is unclear. Thus the mechanisms by which transport is influenced remain speculative and although these data show that functional disturbances occur they give few clues to the precise factors involved. Study of other cytotoxics which act at different sites on cellular metabolism would be of value to elucidate the mechanisms of topical toxicity. All previous studies of cytotoxic enteropathy have, however, considered only the functional derangement associated with gross villous damage.
What are the possible clinical implications of this local toxic effect? In addition to direct exposure from oral doses up to 10% of a single dose of MTX is recycled within the enterohepatic system irrespective of the route of administration,21 and this provides a mechanism by which the jejunal mucosa might be exposed for long periods to potentially toxic drug concentrations.
The precise concentration of MTX in the small gut after oral or parenteral doses is unclear. The only published data showed that in a single case 24 hours after a small dose (5 mg) the jejunal concentrations were 8x 10-9M and 17x 10-9M after oral and intramuscular administration respectively. At five days the concentration was 62 x 10-9M showing considerable enterohepatic recycling.6 It is likely that higher concentrations are found in the small gut during the early absorptive phase after an oral dose or within a few hours of a parenteral dose. With current intermediate dose (500 mg/M2) and high dose (up to 13 g/m2) schedules these concentrations probably exceed 10-6M. Moreover after oral doses the duration of exposure of the small gut to MTX is variable. A group of 'slow absorbers' has been defined in whom serum drug profiles indicate prolonged residence in the small gut.26 In the present study the concentration of 10-6M was chosen as this is generally accepted as the concentration at which the druf exerts a cytotoxic effect on the intestinal mucosa. l Protracted diarrhoea might therefore occur where there is an unusually high amount of MTX excreted in the bile6 and topical toxicity could also explain the prolonged xylose malabsorption associated with intermittent MTX administration in children with leukaemia. Malabsorption is evident for up to three weeks after a single dose of MTX, at which time the jejunal mucosa would be expected to have recovered from any systemic effects. Furthermore jejunal morphometry at this time has been shown to be normal.7 In conclusion these data show that MTX alters small intestinal transport by a previously unrecognised local action which may have an important role in the pathogenesis of malabsorption and diarrhoea seen in some patients on cytotoxic therapy. 
